At­las ramps up a new biotech play­er fo­cused on neu­rol­o­gy, with a $30M round to fund the work

About 6 months ago, Jef­frey Mil­brandt and Aaron DiAnto­nio out of Wash­ing­ton Uni­ver­si­ty pub­lished a high-pro­file pa­per in Neu­ron high­light­ing the role that SARM1 played in the degra­da­tion of ax­ons — a pathol­o­gy that push­es pa­tients with a va­ri­ety of neu­ro­log­i­cal con­di­tions like MS and ALS down a dan­ger­ous path­way.

What they didn’t say at the time was that Ja­son Rhodes, a part­ner at At­las Ven­ture, was al­ready seed­ing the foun­da­tion­al sci­ence work on SARM1 that would go in­to a new com­pa­ny that is hav­ing its com­ing out par­ty to­day. The Cam­bridge, MA-based biotech up­start is called Dis­arm Ther­a­peu­tics, and it’s leap­ing on­to the biotech stage with a $30 mil­lion round to ad­vance a pipeline of SARM1 in­hibitors for a va­ri­ety of dis­eases.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER